TAKE THIS POLL |
|
|
- STOCKS NEWS EUROPE-Gerresheimer rises on Q3 results 15 Oct 2008 15:29 GMT
... STOCKS NEWS EUROPE-Gerresheimer rises on Q3 results | 15 Oct ... "buy" stance on Elan, the maker of MS drug Tysabri. Reuters Messaging 11:26GMT 15Oct2008-Deutz drops on Goldman ...
- STOCKS NEWS EUROPE-Opportunities and risks are "enormous" -FPM 15 Oct 2008 14:18 GMT
... Oct 15 (Reuters) - STOCKS NEWS Reuters Results diary Stocks ... "buy" stance on Elan, the maker of MS drug Tysabri. 11:26GMT 15Oct2008-Deutz drops on Goldman Sachs rating ...
- STOCKS NEWS EUROPE-Opportunities and risks are 'enormous' -FPM 15 Oct 2008 13:50 GMT
... Oct 15 (Reuters) - STOCKS NEWS Reuters Results diary Stocks ... 'buy' stance on Elan, the maker of MS drug Tysabri. Reuters Messaging 11:26GMT 15Oct2008-Deutz drops on Goldman ...
- €1bn EDT sale hit by crunch 15 Oct 2008 07:50 GMT
... that the potential €1bn sale of its drug development ... said the number of patients taking the MS treatment continued to grow in the third quarter. ...
- ISEQ trims gains as banks lose shine 14 Oct 2008 17:16 GMT
... ISEQ trims gains as banks lose shine Having initially jumped ... and answers session about its flagship drug Tysabri. Elan remains very focussed on cash generation ...
- ISEQ jumps 5pc on US bank bailout 14 Oct 2008 12:14 GMT
... ISEQ jumps 5pc on US bank bailout Hopes that an ... and answers session about its flagship drug Tysabri. Elan remains very focussed on cash generation ...
- Zacks Analyst Blog Highlights: Biogen Idec, Inc., Royal Bank of Scotland Group Plc., Lloyds TSB Group Plc., HBOS Plc. and Strayer Education, Inc. 14 Oct 2008 11:51 GMT
... Zacks Analyst Blog Highlights: Biogen Idec, Inc., Royal Bank of Scotland ... the year, driven by solid sales of multiple sclerosis drugs Avonex and Tysabri. Yet just when things were looking solid ...
- Four days on 110cc all for a good cause 13 Oct 2008 15:51 GMT
... marketing manager Anita Gowers said the money raised from the ride would go towards multiple sclerosis research. "It's been amazing, every single person has raised more than $500 each," ...
- Overview and Analysis of the Global Generic Drug Industry 13 Oct 2008 11:50 GMT
... Top 5 Companies by 52-Week Stock Price Change ( click on charts to ... to produce a generic form of the multiple sclerosis drug Copaxone, which is made by ...
- Clothing venture fits pair to a T 13 Oct 2008 05:50 GMT
... The shirt sells for $30, and $1 of each sale is donated to the Multiple Sclerosis Research Foundation, he said. Poissonnier said the business was launched carefully in March. ...
- Supporting Loved Ones In Nursing Homes Enhances Daily Living 11 Oct 2008 03:50 GMT
... Supporting Loved Ones In Nursing Homes Enhances Daily Living EDMC (ARA) - According to the ...
- Biogen withdraws arthritis drug after trial failures 10 Oct 2008 18:29 GMT
... has stopped the development of its rheumatoid arthritis drug, baminercept, after it ... cartilage. In August, Biogen announced that its multiple sclerosis drug Tysabri was linked to two cases ... begun Phase 2/3 trials of the battered MS drug for treating multiple myeloma. With 4,300 workers ...
- The Early Edge: Alcoa, Biogen Idec, DreamWorks Animation, and MasterCard 10 Oct 2008 14:33 GMT
... The Early Edge: Alcoa, Biogen Idec, DreamWorks Animation, and MasterCard Friday October ... that the focus will remain on BIIB's multiple sclerosis drugs Tysabri and Avonex. BIIB is slightly lower this ...
- Alcoa, Biogen Idec, DreamWorks Animation, and MasterCard 10 Oct 2008 13:35 GMT
... Today features a potential downgrade for Alcoa (AA), brokerage comment on ... that the focus will remain on BIIB's multiple sclerosis drugs Tysabri and Avonex. BIIB is slightly lower this ...
- Analysts brush off Biogen Idec's decision to end development of experimental arthritis drug 10 Oct 2008 12:24 GMT
... "We view this as largely a nonevent for Biogen shares as baminercept ... said the focus will remain on Biogen's multiple sclerosis drugs Tysabri and Avonex. Wall Street has so far ...
- Ahead of the Bell: Biogen Idec 10 Oct 2008 12:19 GMT
... On Thursday, the biotechnology company said it would end development of ... said the focus will remain on Biogen's multiple sclerosis drugs Tysabri and Avonex. Wall Street has so far ...
- Biogen discontinues research on RA drug baminercept 10 Oct 2008 10:32 GMT
... Biogen discontinues research on RA drug baminercept Biogen Idec has suffered ... infection, progressive multifocal leukoencephalopathy, linked to the multiple sclerosis drug Tysabri (natalizumab). "Biogen Idec has suffered a setback ...
- UPDATE 2-Biogen discontinues experimental arthritis drug 10 Oct 2008 06:52 GMT
... LOS ANGELES, Oct 10, 2008 (Reuters via COMTEX) -- Biogen Idec Inc said ... infection that has been linked to Biogen's multiple sclerosis drug Tysabri. Biogen Idec shares, which fell 3.4 percent ...
- New from MS Research: URank - 'Search Gets Organized' 10 Oct 2008 05:56 GMT
... The implementation is fairly straightforward: in the search box on the top ... Oct 2008, 02:08 PM with New from MS Research: URank - “Search Gets Organized” Just in ...
- Biogen discontinues experimental arthritis drug 10 Oct 2008 03:44 GMT
... LOS ANGELES (Reuters) - Biogen Idec Inc said on Thursday it will ... infection that has been linked to Biogen's multiple sclerosis drug Tysabri. Biogen Idec shares, which fell 3.4 percent ...
1 - 25 of 55 next >
News by PR Newswire
|
